Residency · Residency · Otolaryngology
Lateral Skull Base: Acoustic Neuroma (Vestibular Schwannoma)
Introduction
Vestibular schwannomas (commonly termed acoustic neuromas) are benign tumors arising from the Schwann cells of the vestibular portion of cranial nerve VIII. They represent the most common tumor of the cerebellopontine angle (CPA), accounting for approximately 80% of CPA lesions. Management requires understanding of lateral skull base anatomy, audiologic assessment, and the nuances of surgical versus conservative approaches.
Epidemiology and Pathophysiology
Incidence: approximately 1-2 per 100,000 per year. Peak presentation: 4th-6th decades of life. Most arise from the inferior vestibular nerve at the Obersteiner-Redlich zone (glial-Schwann cell junction). Bilateral vestibular schwannomas are pathognomonic for Neurofibromatosis Type 2 (NF2) — autosomal dominant, chromosome 22q12 mutation. Slow-growing (1-2 mm/year on average), but growth rate is variable.
Clinical Presentation
Asymmetric sensorineural hearing loss (SNHL): most common presenting symptom (>90%). Tinnitus: unilateral, often high-pitched. Imbalance and unsteadiness (true vertigo is less common). Facial numbness (CN V compression) with larger tumors. Facial weakness (CN VII) is rare at presentation but indicates large tumor. Brainstem compression: hydrocephalus, ataxia, headache (late findings).
Diagnostic Workup
Audiometry
Asymmetric SNHL with poor speech discrimination disproportionate to pure tone thresholds. ABR (auditory brainstem response): prolonged wave I-V interpeak latency; sensitivity ~95% for tumors >1 cm.
Imaging
MRI with gadolinium: gold standard; enhancing mass in the IAC/CPA. Evaluate tumor size, relationship to brainstem and cranial nerves, presence of hydrocephalus. CT of temporal bone: assess bony anatomy of the IAC for surgical planning.
Classification
Koos Grading System
| Grade | Description | Size |
|---|---|---|
| I | Intracanalicular tumor | Confined to IAC |
| II | Extends into CPA | <2 cm |
| III | Occupies CPA cistern, no brainstem contact | 2-3 cm |
| IV | Brainstem compression | >3 cm |
Grade I: intracanalicular tumor. Grade II: extends into CPA, <2 cm. Grade III: occupies CPA cistern, 2-3 cm, no brainstem contact. Grade IV: >3 cm, brainstem compression.
Management Options
Observation (Watch and Wait)
Appropriate for small tumors, elderly patients, only-hearing ears. Serial MRI at 6 months, then annually, Up to 50% of tumors show no growth over 5 years.
Stereotactic Radiosurgery (Gamma Knife / CyberKnife)
Typically for tumors <3 cm without significant brainstem compression. Tumor control rates: 90-95% at 10 years. Hearing preservation: 50-70% at 5 years. Risk of delayed facial neuropathy: 1-5%.
Microsurgical Resection
| Approach | Hearing Preservation | Best Indication | Key Advantage |
|---|---|---|---|
| Translabyrinthine | No (sacrificed) | Non-serviceable hearing | Excellent facial nerve exposure |
| Retrosigmoid (suboccipital) | Possible (30-50%) | Medial tumors with serviceable hearing | Good access to CPA |
| Middle cranial fossa | Best (50-70%) | Small intracanalicular tumors | Superior hearing preservation |
Translabyrinthine approach: sacrifices hearing; excellent facial nerve exposure; ideal for non-serviceable hearing. Retrosigmoid (suboccipital) approach: hearing preservation possible; good for medial tumors. Middle cranial fossa approach: best hearing preservation for small intracanalicular tumors with serviceable hearing.
Surgical Considerations
Intraoperative facial nerve monitoring (EMG) is mandatory. ABR monitoring for hearing preservation approaches. Facial nerve is typically displaced anteriorly and superiorly by the tumor. Goal is gross total resection while preserving facial nerve function. A thin rind of tumor may be left on the facial nerve to preserve function.
Outcomes and Complications
Facial nerve outcomes (House-Brackmann scale): HB I-II in 80-95% for experienced surgeons. Hearing preservation: 50-70% for middle fossa, 30-50% for retrosigmoid. CSF leak: 5-15%, managed with lumbar drain or wound revision. Headache: common after retrosigmoid approach. Meningitis: 1-2%.
Key Clinical Pearls
Any patient with asymmetric SNHL or unilateral tinnitus should have MRI to rule out vestibular schwannoma. NF2 should be suspected in any patient with bilateral vestibular schwannomas or a young patient with unilateral VS. The translabyrinthine approach provides the best facial nerve visualization but sacrifices all residual hearing. Small, stable tumors in elderly patients are often best managed with observation. Serviceable hearing is defined as AAO-HNS Class A or B (PTA <=50 dB, SDS >=50%).
References
- Carlson ML, Link MJ, Wanna GB, Driscoll CLW. Management of sporadic vestibular schwannoma. Otolaryngol Clin North Am. 2015;48(3):407-422.
- Kanzaki J, Tos M, Sanna M, et al. New and modified reporting systems from the Consensus Meeting on Systems for Reporting Results in Vestibular Schwannoma. Otol Neurotol. 2003;24(4):642-649.
- Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22(1):31-45.
- Brackmann DE, Cullen RD, Fisher LM. Facial nerve function after translabyrinthine vestibular schwannoma surgery. Otolaryngol Head Neck Surg. 2007;136(5):773-777.
For the intern
At 3am, your priorities are acute complications: sudden facial weakness after recent surgery (possible hematoma—call senior immediately), severe headache with vomiting suggesting hydrocephalus (needs urgent imaging), or clear fluid dripping from the nose/ear post-op (CSF leak—elevate head of bed, strict bed rest, notify senior in morning unless profuse). The workup for asymmetric hearing loss, scheduling MRIs, and discussing treatment options with patients can all wait until morning rounds. If a patient presents with new-onset asymmetric hearing loss and wants "an MRI tonight," explain it's not emergent unless accompanied by severe headache, mental status changes, or acute cranial nerve deficits.
Common pitfalls
- Ordering CT instead of MRI with gadolinium: CT misses small intracanalicular tumors. MRI with contrast is the gold standard—don't waste time and radiation with CT unless you're evaluating bony anatomy for surgical planning.
- Reassuring patients that "it's benign so it's no big deal": While histologically benign, these tumors cause significant morbidity through mass effect, hearing loss, and facial nerve injury. Treatment decisions are complex and nuanced.
- Assuming all acoustic neuromas need immediate surgery: Many small tumors remain stable for years. Observation with serial imaging is often appropriate, especially in elderly patients or those with small tumors.
- Forgetting NF2 screening: Any patient under 30 with vestibular schwannoma or anyone with bilateral tumors needs genetic counseling and ophthalmology evaluation for other NF2 stigmata.
Make it stick
You're seeing a 55-year-old woman in clinic for new-onset unilateral tinnitus and decreased hearing in her left ear. She's worried about hearing loss. You perform a quick bedside whisper test, which confirms mild left-sided impairment. Your attending asks what your next step is. You recall from the lecture that asymmetric sensorineural hearing loss (SNHL) is the most common presenting symptom of vestibular schwannoma, which accounts for 80% of cerebellopontine angle lesions. You confidently recommend an MRI of the brain with gadolinium contrast to rule out this tumor. This diagnostic step is crucial because early detection allows for a broader range of management options.
If you remember one thing
Asymmetric sensorineural hearing loss or unilateral tinnitus warrants an MRI with gadolinium to rule out vestibular schwannoma. Management options are complex, ranging from observation to radiation or surgery, tailored to tumor size, growth, and patient factors.